Directions Website

TRC TRC has over 40 years specialised in the production of quality products for innovative research.

🏆 Present your biomarker research and win up to $6,500 / €6,000 worth of stable isotope-labelled standards, plus an Amaz...
10/14/2026

🏆 Present your biomarker research and win up to $6,500 / €6,000 worth of stable isotope-labelled standards, plus an Amazon eGift card!

✨If your research involves drugs, biomarkers or stable isotope-labelled compounds, enter our Virtual Poster Competition for the chance to showcase your work to a panel of scientific experts.

Finalists will be invited to present their research during a live webinar in February 2027.

Prizes
🥇 1st Place: $6,500 / €6,000 worth of stable isotope-labelled standards + $250 Amazon eGift card
🥈 2nd Place: $200 Amazon eGift card
🥉 3rd Place: $125 Amazon eGift card

📅 Submission deadline: 31 December 2026

Give your research the visibility it deserves and be recognised by leading experts in the field. 🔗 Submit your abstract here: https://ow.ly/jr7j50ZWPlK

⬇️ Download the flyer for full competition details, eligibility criteria and submission information.

10/13/2026

How do assigned values, measurement uncertainty, and traceability contribute to confidence in pharmaceutical testing?

Join our upcoming webinar "Working Standards in Pharmaceutical Quality Control" to explore the science behind working standards and discuss practical strategies for establishing, qualifying, and managing them in routine pharmaceutical quality control.

What you'll learn:
✅ Approaches to establishing and qualifying working standards for compendial and non-compendial testing
✅ Practical considerations for lifecycle management and outsourcing
✅ Insights from a real-world customer case study
✅ LGC's API working standard solutions

📅 Thursday 12 November 2026
14:00 GMT | 15:00 CET | 09:00 EST | 06:00 PST

⏳ Register early to secure your place: https://ow.ly/mslT50ZWMcX

🔬 New additions to our bioanalytical portfolioOur portfolio continues to grow, with new bioanalytical standards supporti...
10/08/2026

🔬 New additions to our bioanalytical portfolio

Our portfolio continues to grow, with new bioanalytical standards supporting pharmaceutical development, clinical research and testing.

Whether you're developing methods, quantifying analytes or conducting pharmacokinetic studies, these new API and metabolite standards can:

✅ Improve quantification accuracy
✅ Support method development
✅ Increase analytical confidence

👇Swipe through to discover the latest additions or click here to explore our bioanalytical portfolio: https://ow.ly/zgl450ZVKlt

Twelve months ago, we held the grand opening of our Organic Chemistry Synthesis Centre of Excellence in Toronto!  👏🗨️Thi...
10/02/2026

Twelve months ago, we held the grand opening of our Organic Chemistry Synthesis Centre of Excellence in Toronto! 👏

🗨️This week, we’re sharing the thoughts of four of our site leaders on how the new facility is helping them and their colleagues, as well as TRC’s ability to better serve its customers worldwide.

Q: What impact has the new centre of excellence had on your team, function, customers, or the wider business?
A: Enoch Koo, America Ops, Synthetic Chemistry, OpEx & cPMO

🤝“The new site’s capabilities have deepened and expanded our customer relations and partnerships – both by bringing new products to market, and by helping us to better serve our end customers.”

Q: What is one key lesson or insight you've gained during the first year of operating from the site?
A: Jennifer Merchant, Senior Manager, Process Excellence

👥“The value of having everyone together under one roof, which has created more opportunities for collaboration, faster problem solving, and stronger relationships across teams.
Conversations that may have taken days through emails or meetings can now be resolved in a matter of minutes. That new level of connection has been instrumental in helping us grow as a site.”

Q: What has impressed you most about the people and culture at the new site?
A: Mulhinm Javid, Director, Financial Planning and Analysis

💡“I think it’s the strong sense of collaboration, engagement, and genuine enthusiasm - about the site's future, and the role it can play in supporting our continued growth and success.
The facility has created a great environment for people to connect, share ideas, and work together more effectively.
I consistently hear exceptional feedback about both the workplace experience and the positive culture that is developing.”

Q: What are you most excited about for the future of this centre of excellence and its continued growth?
A: Thomas Lau, Director, Quality

☑️“Since moving into the new building we have welcomed many visitors - including both existing and potential customers - and their feedback is consistently positive about the site and the LGC offer.
This strong impression has not only reinforced confidence in the Toronto site but also translated into meaningful business interest. We’ve had several discussions that may lead to future partnerships and contribute to our continued growth.”

What you measure depends on what you separate.📊In LC–UV potency assays, chromatographic selectivity underpins quantitati...
09/30/2026

What you measure depends on what you separate.

📊In LC–UV potency assays, chromatographic selectivity underpins quantitative accuracy. Without adequate separation, co-eluting impurities, degradants or excipients can contribute to the measured response, introducing systematic bias into the reported potency.

💡Our latest application note explores practical strategies for building chromatographic selectivity and improving confidence in reported potency measurements.

⬇️Download the application note: https://ow.ly/S4nf50ZT3XZ

Since nitrosamine impurities were first identified in medicines, the pharmaceutical industry has relied on highly conser...
09/29/2026

Since nitrosamine impurities were first identified in medicines, the pharmaceutical industry has relied on highly conservative approaches to protect patient safety. While appropriate, this has also resulted in extensive testing and significant resource demands.

During our recent panel discussion (▶️Watch on demand: https://ow.ly/PKoy50ZPKSN ),
toxicologist George Johnson suggested that 50–90% of today's nitrosamine testing could eventually become unnecessary if emerging scientific approaches are adopted by regulators.

📝 A recent study led by scientists at Eli Lilly and Company helps explain why. It proposes a complementary pathway in which quantitative in vivo mutagenicity data (TGR) could support the derivation of compound-specific acceptable intake limits, moving risk assessment towards a more evidence-based approach. Read the study at https://ow.ly/zYiA50ZPKSM

🎉It’s been a year since the grand opening of our Organic Chemistry Synthesis Centre of Excellence in Toronto!That makes ...
09/25/2026

🎉It’s been a year since the grand opening of our Organic Chemistry Synthesis Centre of Excellence in Toronto!

That makes it the perfect time to ask our site leaders about how the new facility is helping them, their colleagues, and TRC’s ability to better serve its customers worldwide.

Q: Looking back on the past year, what achievement or milestone are you most proud of?
A: Jose Rodezno, Senior Director, Operations and Synthetic Chemistry

🙌“I’m particularly proud of introducing the Electronic Laboratory Notebook (ELN) system. That really was a milestone achievement.

Getting there required strong collaboration across our teams – to modernise our processes, improve data integrity and traceability, and create a more efficient way of working.

The new system represents a significant step forward in our digital transformation journey – one that will deliver long-term benefits for our employees, customers, and the environment.”

Q: What has impressed you most about the people and culture at the new site?
A: Damian Chung, Director, End to End Supply Chain

👩🏽‍🔬“Our people, and their ability to engage collectively as a team.

The team showed incredible adaptability and collaboration, doing whatever was needed to make this a successful and safe move.

Then, once we were in the new facility, they also impressed me with how quickly they adapted to their new spaces and new processes – making it a seamless transition.”

Q: What are you most excited about for the future of the Toronto site and its continued growth?
A: Rathika Jayasinghe, HR Director Toronto

💡“The tremendous opportunity that this new facility creates to accelerate growth, innovation, and collaboration.

Being together in a single, integrated, and world class environment has helped create stronger connections between people, ideas, and processes - enabling faster problem-solving, greater knowledge sharing, and increased operational efficiency.

Looking ahead, I see significant opportunities to enhance process excellence, drive continuous improvement, and further expand our capabilities in organic synthesis.

And all of this will enable our site to support new customer opportunities, accelerate product development, and continue growing as a strategic hub within the organisation.”

09/24/2026

Our tailored range of research compounds can help you get the very best from your GLP 1 project. 👇

With sales of weight loss products booming - and GLP1s also showing promise as treatments for cancer, addiction, Alzheimer's, and more - it's never been so important to get your research and product development right.

Our focused selection of GLP 1 agonists and analogues is now available to support your method development, assay optimisation, and reference testing needs.

We also offer rapid global distribution - ensuring that you get the tools you need, when you need them. 🔗Discover the range: https://ow.ly/ekXu50ZPOxN

📚  Spotlight Why do some populations experience a higher risk of to***co-related cancer despite similar smoking behaviou...
09/23/2026

📚 Spotlight
Why do some populations experience a higher risk of to***co-related cancer despite similar smoking behaviours?

Researchers have explored this question for decades.

📝A new study led by US scientists investigates whether inherited differences in to***co carcinogen metabolism could be part of the explanation. DOI: 10.1007/s00204-026-04505-w

Focusing on NNK, a major to***co-specific nitrosamine carcinogen, the authors found that smokers with higher African genetic ancestry were more likely to exhibit a poor metaboliser phenotype. They also identified ancestry-associated genetic variants involved in to***co carcinogen metabolism and detoxification.

The findings suggest that people smoking the same number of ci******es may not receive the same biological dose of carcinogen exposure, potentially contributing to differences in to***co-related cancer risk.

✨It's a fascinating example of how biomarkers, molecular toxicology and genetics are helping us better understand individual susceptibility to carcinogens—and could ultimately support more personalised approaches to cancer prevention.

This study was supported by to***co nitrosamine research chemicals from TRC. 🔬Find out more: https://ow.ly/GE5m50ZPIV2

💊Extractables and leachables remain a critical consideration in pharmaceutical development, packaging selection, and lif...
09/22/2026

💊Extractables and leachables remain a critical consideration in pharmaceutical development, packaging selection, and lifecycle management.

👇Our latest flyer explores the evolving ICH Q3E framework and highlights reference standards that can support analytical testing, toxicological assessment and regulatory readiness.

⬇️Download it to discover more: https://ow.ly/EBgb50ZPOrw

Address

20 Martin Ross Avenue
Toronto, ON
M3J2K8

Alerts

Be the first to know and let us send you an email when TRC posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share